Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16654403 | 0.84 | FGFR4 (0.41) | FGFR1FGFR4CYP2C19 | |
| SCHEMBL16654119 | 0.82 | FGFR3 (0.35) | FGFR1FGFR4CYP2C19 | |
| SCHEMBL16655790 | 0.82 | FGFR1 (0.44) | FGFR1NPC1RAB9A | |
| SCHEMBL22157649 | 0.80 | FGFR4 (0.32) | FGFR1FGFR4 | |
| SCHEMBL16665253 | 0.76 | FGFR1 (0.33) | FGFR1FGFR4CYP2C19 | |
| SCHEMBL28767434 | 0.72 | FGFR1 (0.33) | FGFR1FGFR4CYP2C19 | |
| SCHEMBL17740814 | 0.71 | FGFR4 (0.49) | FGFR1FGFR4 | |
| SCHEMBL28767438 | 0.71 | FGFR3 (0.42) | FGFR1FGFR4CYP1A2CYP2C19 | |
| SCHEMBL20610863 | 0.70 | — | — | |
| SCHEMBL28768907 | 0.70 | FGFR3 (0.40) | FGFR1FGFR4CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3421457-B1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2021-10-06 | — | — | EP | disclosed |
| US-10912774-B2 | Pyrimidine FGFR4 inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-02-09 | — | — | US | disclosed |
| US-10912774-B2 | Pyrimidine FGFR4 inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-02-09 | — | — | US | disclosed |
| US-20200206222-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-07-02 | — | — | US | disclosed |
| US-20200206222-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-07-02 | — | — | US | disclosed |
| EP-3421457-A1 | PYRIMIDINE FGFR4 INHIBITORS | Eisai R&D Management Co., Ltd. (JP) | 2019-01-02 | — | — | EP | disclosed |
| EP-3057943-B1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2018-04-25 | — | — | EP | disclosed |
| US-20170360785-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20170360785-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20170360785-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20170007601-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-01-12 | — | — | US | disclosed |
| WO-2016164754-A1 | FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-10-13 | — | — | WO | disclosed |
| WO-2016164754-A1 | FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-10-13 | — | — | WO | disclosed |
| US-9434697-B2 | Pyrimidine FGFR4 inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-06 | — | — | US | disclosed |
| US-9434697-B2 | Pyrimidine FGFR4 inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-06 | — | — | US | disclosed |
| US-9434697-B2 | Pyrimidine FGFR4 inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-06 | — | — | US | disclosed |
| US-20160130237-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-05-12 | — | — | US | disclosed |
| US-20160130237-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-05-12 | — | — | US | disclosed |
| US-20160130237-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-05-12 | — | — | US | disclosed |
| WO-2015057963-A1 | FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360785-A1 | PYRIMIDINE FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | FGFR1 2/4885CHRNA7 4818/4885KDM4E 445/4885 |
| US-10912774-B2 | Pyrimidine FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | FGFR1 2/4885CHRNA7 4818/4885KDM4E 445/4885 |
| US-20160130237-A1 | PYRIMIDINE FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | FGFR1 2/4885CHRNA7 4818/4885KDM4E 445/4885 |
| US-20170007601-A1 | PYRIMIDINE FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | FGFR1 2/4885CHRNA7 4818/4885KDM4E 445/4885 |
| US-20200206222-A1 | PYRIMIDINE FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | FGFR1 2/4885CHRNA7 4818/4885KDM4E 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.